Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer

Abstract Overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is critical in combating EGFR-mutant non-small cell lung cancer (NSCLC). We tried to construct a novel therapeutic strategy to conquer the resistance to second-and third-generation EGFR...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Akiko Takahashi, Masahiro Seike, Mika Chiba, Satoshi Takahashi, Shinji Nakamichi, Masaru Matsumoto, Susumu Takeuchi, Yuji Minegishi, Rintaro Noro, Shinobu Kunugi, Kaoru Kubota, Akihiko Gemma
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Osimertinib Afatinib Ankyrin Repeat Domain (ANKRD1) Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKIs) EGFR-mutant NSCLC Patients Medicine R Science Q
Acceso en línea:	https://doaj.org/article/2d4c5449621342aa816f7c0089346a66
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer

Ejemplares similares